News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shenzhen Hepalink Pharmaceutical Co., Ltd Invests $36.5 Million In Kymab's C Round



11/28/2016 10:48:16 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Shenzhen Hepalink Pharma invested $36.5 million in Kymab Group, a British mAb startup that develops first-in-class candidates. The investment was part of a $100 million Series C round. Founded in 2010, Kymab expects to begin clinical trials of its most advanced candidate next year. Hepalink, which started as a heparin API supplier, has been expanding its product mix through M&A. Also, in 2015, Hepalink paid $206 million to acquire a US biologics contract development/manufacturing company, Cytovance, which Kymab cited as an important addition to its working relationships.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES